Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.

Haematologica

Volumn 87, Issue 12, 2002, Pages

  Fruehauf, Stefan ^a   Topaly, Julian ^a   Buss, Eike C ^a   Schad, Moritz ^a   Goerner, Martin ^a   Zeller, W Jens ^a   Ho, Anthony D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION; SALVAGE THERAPY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PIPERAZINES; PYRIMIDINES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING;

EID: 1642331267     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)